Last reviewed · How we verify
Rotigotine PR2.2.1
At a glance
| Generic name | Rotigotine PR2.2.1 |
|---|---|
| Sponsor | UCB Pharma SA |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Single-site, Open-label, Randomized, Cross-over Study in Healthy Chinese Subjects to Evaluate the Bioequivalence of Single-dose Rotigotine Transdermal Patch Comparing 2 Different Formulations (PHASE1)
- Study in Healthy Volunteers to Prove That Two Different Formulations of Rotigotine Patches Deliver Equivalent Drug Amount to the Body (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rotigotine PR2.2.1 CI brief — competitive landscape report
- Rotigotine PR2.2.1 updates RSS · CI watch RSS
- UCB Pharma SA portfolio CI